Calendario›SNY›SAR444881
SAR444881
Ensayo de Sanofi en Cancer · Neoplasm (del registro, en inglés).
Más ensayos de: Cáncer.
- Fase
- Fase 1/2
- Estado
- Interrumpido
- Participantes
- 125
- Centros
- 18
- Fin del objetivo primario
- jul 2025
Título oficial en el registro (en inglés): Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en abr 2021.
Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Early discontinuation based on strategic sponsor decision not driven by any safety concerns».
De principio a fin
- Empieza el ensayo (abr 2021)
- Lectura de resultados jul 2025 (real)
- Hoy
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Qué mide
Part 1: Sub-Parts 1A, 1B and 1C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) (From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment (considering maximum duration of treatment exposure) i.e., up to approximately Part 1-Sub-Part 1A: 51 weeks, Sub-Part 1B: 126.7 weeks, Sub-Part 1C: 99.3 weeks) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe study enrolled advanced cancer participants with unresectable or metastatic disease who were refractory to or were not candidates for standard approved therapy. The study comprised of two parts - a dose escalation phase (Part 1) and a dose optimization/expansion phase (Part 2). Part 1 was comprised of three sub-parts: SAR444881 administered alone (Sub-Part 1A), SAR444881 administered in combination with pembrolizumab (Sub-Part 1B), and SAR444881 administered in combination with cetuximab (Sub-Part 1C). Part 2 was composed of two sub-parts: a dose optimization part where up to two doses of SAR444881 per indication were administered in combination with pembrolizumab, cetuximab, and/or carboplatin and pemetrexed (Sub-Part 2A); and a dose expansion part where SAR444881 was administered alone (Sub-Part 2B). In Sub-Part 2A, a two-stage design would be implemented to conduct dose optimization for each indication with combination therapy- Stage 1 (Preliminary Assessment) and Stage 2 (Randomization). Study was non-randomized except Stage 2 of Sub-Part 2A which would use randomization.
Más ensayos de SNY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Avalglucosidase alfa · Mini-COMET | Fase 2 | En marcha, sin reclutar | sep 2019 (real) |
| Yellow fever vaccine | Fase 2 | En marcha, sin reclutar | may 2022 (real) |
| Yellow fever vaccine · VYF02 | Fase 2 | En marcha, sin reclutar | jun 2022 (real) |
| SAR441344 IV | Fase 2 | En marcha, sin reclutar | sep 2022 (real) |
| Meningococcal Polysaccharide | Fase 3 | En marcha, sin reclutar | mar 2023 (real) |
| rilzabrutinib · LUMINA 2 | Fase 2 | En marcha, sin reclutar | may 2024 (real) |
Todos los de SNY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT04717375), actualizada en sep 2026.